![](/img/cover-not-exists.png)
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)
Brandes, A A, Tosoni, A, Cavallo, G, Bertorelle, R, Gioia, V, Franceschi, E, Biscuola, M, Blatt, V, Crinò, L, Ermani, MVolume:
95
Language:
english
Journal:
British Journal of Cancer
DOI:
10.1038/sj.bjc.6603376
Date:
November, 2006
File:
PDF, 103 KB
english, 2006